Producer of CES®

Skip to content

CTA Commends Trump Administration's Consumer-Centric Approach on ONC, CMS Rulings

June 3, 2019

  • Danielle Cassagnol Industry Communications
Article Summary

The following statement is attributed to Gary Shapiro, president and CEO, Consumer Technology Association (CTA), regarding the Trump administration's Office of the National Coordinator for Health Information Technology (ONC) and Centers for Medicare and Medicaid Services (CMS) proposed rulings regarding increased interoperability and access to electronic health information:

The following statement is attributed to Gary Shapiro, president and CEO, Consumer Technology Association (CTA), regarding the Trump administration's Office of the National Coordinator for Health Information Technology (ONC) and Centers for Medicare and Medicaid Services (CMS) proposed rulings regarding increased interoperability and access to electronic health information:
 
"Kudos to the Trump administration for prioritizing health care data - by requiring, with exceptions, that health care organizations give patients their medical records and health plan data in a free, secure, computable format. When patients have the ability to control and share their data, they'll get the most effective treatments. And unfettered access to patient data means patients can make smarter choices on treatment options, curbing growing medical costs.
 
"Our Health and Fitness Technology Division - focused on how consumer-based, tech-enabled health solutions can deliver better outcomes and cut health care expenses - will help government propel health care into the future. And CTA member companies - including Humetrix, creator of the first Blue Button enabled mobile app - will put the access, storage and sharing of health records right in patients' hands.
 
"We look forward to continuing to work closely with the ONC and CMS to revolutionize health care in the U.S.  and change patients' lives for the better."
 
Please reach out directly for CTA's comments on the ONC's Proposed 21st Century Cures Act Rule and comments on CMS' Proposed Interoperability and Patient Access Rule.
 
Today, CTA also submitted comments in response to the Food and Drug Administration framework for artificial intelligence software as a medical device whitepaper. Please reach out directly if interested in a copy.

More Press Releases

  • CTA

    CTA CEO: Tech Exclusion Not a Permanent Solution

    April 14, 2025
  • CTA

    CTA Applauds Tariff Pause

    April 9, 2025
  • CTA

    Consumer Technology Association Releases 2025 State Innovation Scorecard

    April 8, 2025
  • CTA

    CTA Launches Reimagined Website to Enhance User Experience

    April 3, 2025